Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.

Smith RA, Raugi DN, Wu VH, Leong SS, Parker KM, Oakes MK, Sow PS, Ba S, Seydi M, Gottlieb GS; University of Washington-Dakar HIV-2 Study Group.

Antimicrob Agents Chemother. 2015 Dec;59(12):7437-46. doi: 10.1128/AAC.01326-15. Epub 2015 Sep 21.

2.

Current perspectives on HIV-1 antiretroviral drug resistance.

Iyidogan P, Anderson KS.

Viruses. 2014 Oct 24;6(10):4095-139. doi: 10.3390/v6104095. Review.

3.
4.

In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.

Li Z, Terry B, Olds W, Protack T, Deminie C, Minassian B, Nowicka-Sans B, Sun Y, Dicker I, Hwang C, Lataillade M, Hanna GJ, Krystal M.

Antimicrob Agents Chemother. 2013 Nov;57(11):5500-8. doi: 10.1128/AAC.01195-13. Epub 2013 Aug 26.

5.

Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors.

Hurwitz SJ, Schinazi RF.

Drug Discov Today Technol. 2012 Fall;9(3):e183-e193.

6.

From the chemistry of epoxy-sugar nucleosides to the discovery of anti-HIV agent 4'-ethynylstavudine-Festinavir.

Haraguchi K, Takeda S, Kubota Y, Kumamoto H, Tanaka H, Hamasaki T, Baba M, Paintsil E, Cheng YC.

Curr Pharm Des. 2013;19(10):1880-97. Review.

7.
8.

Balancing antiviral potency and host toxicity: identifying a nucleotide inhibitor with an optimal kinetic phenotype for HIV-1 reverse transcriptase.

Sohl CD, Kasiviswanathan R, Kim J, Pradere U, Schinazi RF, Copeland WC, Mitsuya H, Baba M, Anderson KS.

Mol Pharmacol. 2012 Jul;82(1):125-33. doi: 10.1124/mol.112.078758. Epub 2012 Apr 18.

9.
10.

Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.

Yang G, Paintsil E, Dutschman GE, Grill SP, Wang CJ, Wang J, Tanaka H, Hamasaki T, Baba M, Cheng YC.

Antimicrob Agents Chemother. 2009 Nov;53(11):4640-6. doi: 10.1128/AAC.00686-09. Epub 2009 Aug 24.

11.

Retention of metabolites of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel anti-human immunodeficiency virus type 1 thymidine analog, in cells.

Wang X, Tanaka H, Baba M, Cheng YC.

Antimicrob Agents Chemother. 2009 Aug;53(8):3317-24. doi: 10.1128/AAC.00302-09. Epub 2009 May 26.

12.

Comparative study of the persistence of anti-HIV activity of deoxynucleoside HIV reverse transcriptase inhibitors after removal from culture.

Paintsil E, Grill SP, Dutschman GE, Cheng YC.

AIDS Res Ther. 2009 Apr 22;6:5. doi: 10.1186/1742-6405-6-5.

13.

Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase by a stavudine analogue, 4'-ethynyl stavudine triphosphate.

Yang G, Wang J, Cheng Y, Dutschman GE, Tanaka H, Baba M, Cheng YC.

Antimicrob Agents Chemother. 2008 Jun;52(6):2035-42. doi: 10.1128/AAC.00083-08. Epub 2008 Apr 7.

14.

Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.

Paintsil E, Dutschman GE, Hu R, Grill SP, Lam W, Baba M, Tanaka H, Cheng YC.

Antimicrob Agents Chemother. 2007 Nov;51(11):3870-9. Epub 2007 Aug 27.

15.

Comparison of the phosphorylation of 4'-ethynyl 2',3'-dihydro-3'-deoxythymidine with that of other anti-human immunodeficiency virus thymidine analogs.

Hsu CH, Hu R, Dutschman GE, Yang G, Krishnan P, Tanaka H, Baba M, Cheng YC.

Antimicrob Agents Chemother. 2007 May;51(5):1687-93. Epub 2007 Mar 12.

16.

Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro.

Nitanda T, Wang X, Kumamoto H, Haraguchi K, Tanaka H, Cheng YC, Baba M.

Antimicrob Agents Chemother. 2005 Aug;49(8):3355-60.

Supplemental Content

Support Center